Jan Van Bocxlaer
Overview
Explore the profile of Jan Van Bocxlaer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
77
Citations
526
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
De Nys L, Barzegar-Fallah A, Lanckmans K, Steurbaut S, Beckwee D, de Haar-Holleman A, et al.
Cancers (Basel)
. 2025 Jan;
17(1.
PMID: 39796679
: Paclitaxel (PTX), a commonly used chemotherapy for breast cancer (BC), is associated with dose-limiting toxicities (DLTs) such as peripheral neuropathy and neutropenia. These toxicities frequently lead to dose reductions,...
2.
De Sutter P, Hermans E, De Cock P, Van Bocxlaer J, Gasthuys E, Vermeulen A
Clin Pharmacokinet
. 2024 Jul;
63(7):965-980.
PMID: 38955946
Background And Objective: The interstitial fluid of tissues is the effect site for antibiotics targeting extracellular pathogens. Microdialysis studies investigating these concentrations in muscle and subcutaneous tissue have reported notable...
3.
Lootens O, De Boevre M, Gasthuys E, De Saeger S, Van Bocxlaer J, Vermeulen A
Toxins (Basel)
. 2024 Jun;
16(6).
PMID: 38922153
Physiologically based pharmacokinetic (PBPK) models were utilized to investigate potential interactions between aflatoxin B1 (AFB1) and efavirenz (EFV), a non-nucleoside reverse transcriptase inhibitor drug and inducer of several CYP enzymes,...
4.
Gasthuys E, van Ovost J, Vande Casteele S, Cosyns S, Ceelen W, Van Bocxlaer J, et al.
J Chromatogr B Analyt Technol Biomed Life Sci
. 2024 Jan;
1233:123980.
PMID: 38215697
Irinotecan (CPT-11), an antineoplastic drug, is used for the treatment of colorectal and pancreatic cancer due to its topoisomerase I inhibitory activity. CPT-11 is a prodrug which is converted to...
5.
Lootens O, De Boevre M, Ning J, Gasthuys E, Van Bocxlaer J, De Saeger S, et al.
Pharmaceutics
. 2023 Mar;
15(3).
PMID: 36986755
Mycotoxins such as aflatoxin B1 (AFB1) are secondary fungal metabolites present in food commodities and part of one's daily exposure, especially in certain regions, e.g., sub-Saharan Africa. AFB1 is mostly...
6.
Lootens O, Vermeulen A, Croubels S, De Saeger S, Van Bocxlaer J, De Boevre M
Toxins (Basel)
. 2022 Dec;
14(12).
PMID: 36548770
Mycotoxin contamination is a global food safety issue leading to major public health concerns. Repeated exposure to multiple mycotoxins not only has repercussions on human health but could theoretically also...
7.
Lootens O, De Boevre M, Gasthuys E, Van Bocxlaer J, Vermeulen A, De Saeger S
Front Microbiol
. 2022 Sep;
13:988083.
PMID: 36110298
Mycotoxins, fungal secondary metabolites, are ubiquitously present in food commodities. Acute exposure to high levels or chronic exposure to low levels has an impact on the human body. The phase...
8.
De Sutter P, Van Haeverbeke M, Van Braeckel E, Van Biervliet S, Van Bocxlaer J, Vermeulen A, et al.
CPT Pharmacometrics Syst Pharmacol
. 2022 Jun;
11(8):951-966.
PMID: 35748042
Cystic fibrosis (CF) has been linked to altered drug disposition in various studies. However, the magnitude of these changes, influencing factors, and underlying mechanisms remain a matter of debate. The...
9.
Nguyen V, Bevernage J, Darville N, Tistaert C, Van Bocxlaer J, Rossenu S, et al.
Mol Pharm
. 2021 Jan;
18(3):952-965.
PMID: 33400546
Pharmacokinetic (PK) profiles of a range of bedaquiline (BDQ) long-acting injectable (LAI) microsuspensions in rats after parenteral (, intramuscular and subcutaneous) administration were correlated with the intrinsic dissolution rate (IDR)...
10.
De Sutter P, Gasthuys E, Van Braeckel E, Schelstraete P, Van Biervliet S, Van Bocxlaer J, et al.
Clin Pharmacokinet
. 2020 Aug;
59(12):1551-1573.
PMID: 32808233
Background: Cystic fibrosis is a lethal inherited disease that affects multiple organs. To provide optimal pharmacological treatment of comorbidities associated with cystic fibrosis, relevant alterations in pharmacokinetics must be known....